{"disease":{"id":"myeloproliferative-neoplasm","name":"myeloproliferative neoplasm"},"drugs":{"marketed":[{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic myeloproliferative neoplasm","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"part-c-met097","indication_name":"Treatment of Myeloproliferative Neoplasms (MPNs)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of myeloproliferative neoplasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02402244","title":"Project: Every Child for Younger Patients With Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":75000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT02252159","title":"Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)","phase":"","overall_status":"COMPLETED","enrollment_count":2544,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT05564390","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04416438","title":"COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias","phase":"","overall_status":"COMPLETED","enrollment_count":1793,"lead_sponsor_name":"French Innovative Leukemia Organisation","has_results":false},{"nct_id":"NCT02953704","title":"Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)","phase":"","overall_status":"COMPLETED","enrollment_count":1469,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT04060485","title":"Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT06334913","title":"A Prospective Patient Reported Outcomes and Wearables Study in Myeloproliferative Neoplasms","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Guy's and St Thomas' NHS Foundation Trust","has_results":false},{"nct_id":"NCT04064060","title":"A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":665,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT04378855","title":"Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY).","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":572,"lead_sponsor_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","has_results":false},{"nct_id":"NCT04385160","title":"Myeloproliferative Neoplasms (MPN) and COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":552,"lead_sponsor_name":"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","has_results":false},{"nct_id":"NCT07410247","title":"MPN Childhood Registry","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"University of Erlangen-Nürnberg Medical School","has_results":false},{"nct_id":"NCT03618485","title":"Registry of Patients With MPNs in Taiwan","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT04192916","title":"Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms","phase":"","overall_status":"COMPLETED","enrollment_count":442,"lead_sponsor_name":"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","has_results":false},{"nct_id":"NCT05745285","title":"Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care","phase":"NA","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT04177576","title":"Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms","phase":"","overall_status":"COMPLETED","enrollment_count":397,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT00003816","title":"Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":361,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT02158858","title":"A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":336,"lead_sponsor_name":"Constellation Pharmaceuticals","has_results":false},{"nct_id":"NCT05554406","title":"Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":335,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06001385","title":"HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":313,"lead_sponsor_name":"Center for International Blood and Marrow Transplant Research","has_results":false},{"nct_id":"NCT06481332","title":"Diagnostic Characterization and Evolution of \"Triple Negative\" Thrombocytosis (CASTETTE)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT03314974","title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT06159816","title":"PREVALENCE STUDY OF PNH CLONES IN PATIENTS WITH NEOPLASIES","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"AUSL Romagna Rimini","has_results":false},{"nct_id":"NCT06034002","title":"A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":290,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT02521493","title":"Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":280,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT00544115","title":"Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":260,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT04771130","title":"A Study of BGB-11417 in Participants With Myeloid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT04942080","title":"Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)","phase":"NA","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"University Hospital, Angers","has_results":false},{"nct_id":"NCT06740916","title":"Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Siriraj Hospital","has_results":false},{"nct_id":"NCT04994158","title":"MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis","phase":"","overall_status":"COMPLETED","enrollment_count":238,"lead_sponsor_name":"Royal Free Hospital NHS Foundation Trust","has_results":false},{"nct_id":"NCT05936359","title":"A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT07441694","title":"Study of INCA036978 in Participants With Myeloproliferative Neoplasms","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":218,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT06059391","title":"CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":216,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05875805","title":"A Telehealth Advance Care Planning Intervention","phase":"NA","overall_status":"RECRUITING","enrollment_count":207,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT02861417","title":"Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":204,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02393248","title":"Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":201,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT06715267","title":"Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP)","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT06313593","title":"A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":186,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT05554419","title":"Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":184,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03386513","title":"Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":179,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03246906","title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":150,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT06468033","title":"P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"PharmaEssentia","has_results":false},{"nct_id":"NCT07150468","title":"Establishment of a Strategy for Preventing Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation by Exploring Immune Mechanisms of Regulatory and Effector T Cells","phase":"","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT04279847","title":"Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":140,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT05600894","title":"Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":132,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03726944","title":"The Feasibility of Delivering Consumer-based Meditation Applications to Myeloproliferative Neoplasm Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Arizona State University","has_results":false},{"nct_id":"NCT01787487","title":"Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07008118","title":"A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT06022341","title":"MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"University Hospital, Angers","has_results":false},{"nct_id":"NCT05440838","title":"Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"University Hospital, Angers","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}